2023
Brief report: The influence of childhood trauma on the effects of delta‐9‐tetrahydrocannabinol in persons with opioid use disorder
Rogan M, Nunes J, Xie C, Sofuoglu M, Pittman B, De Aquino J. Brief report: The influence of childhood trauma on the effects of delta‐9‐tetrahydrocannabinol in persons with opioid use disorder. American Journal On Addictions 2023, 33: 343-346. PMID: 38059660, PMCID: PMC11032222, DOI: 10.1111/ajad.13504.Peer-Reviewed Original ResearchDelta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory study
De Aquino J, Meyerovich J, Xie C, Ranganathan M, Compton P, Pittman B, Rogan M, Sofuoglu M. Delta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory study. Addiction Biology 2023, 28: e13317. PMID: 37644897, PMCID: PMC10468603, DOI: 10.1111/adb.13317.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist therapyAgonist therapyMethadone dosesMethadone therapyPain sensitivityUse disordersPlacebo-controlled laboratory studySynergistic antinociceptive effectCognitive adverse effectsSingle oral dosesRisk-benefit profilePain sensitivity measuresCannabinoid receptor systemAntinociceptive effectTHC doseOral dosesOpioid agonistsAcute effectsCannabinoid agonistsPreclinical studiesAbuse potentialOpioid crisisTherapyReceptor systemDeveloping non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence
Oliveira D, Fontenele R, Weleff J, Sofuoglu M, De Aquino J. Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence. International Review Of Psychiatry 2023, 35: 377-396. PMID: 38299655, PMCID: PMC10835074, DOI: 10.1080/09540261.2023.2229430.Peer-Reviewed Original ResearchOpioid agonist therapyOpioid use disorderNon-opioid analgesicsUse disordersNon-opioid analgesic therapyAlpha-2 adrenergic agonistsMajor public health concernGlial activation inhibitorNon-opioid therapeuticsNovel analgesic strategiesPotential of cannabinoidsPrior opioid exposureOpioid-dependent individualsOpioid-dependent populationsAbuse liability assessmentPublic health concernAnalgesic strategiesAgonist therapyAnalgesic therapyOpioid exposureOUD treatmentPharmacokinetic interactionsGABAergic drugsSignificant morbidityPain typesIntegrating cognitive bias modification for pain and opioid cues into medication for opioid use disorder clinical care: Feasibility, acceptability, and preliminary results
MacLean R, Heapy A, Waters A, Wolkowicz N, Szollosy S, Meyerovich J, Sofuoglu M. Integrating cognitive bias modification for pain and opioid cues into medication for opioid use disorder clinical care: Feasibility, acceptability, and preliminary results. Drug And Alcohol Dependence 2023, 246: 109857. PMID: 37004461, PMCID: PMC10189744, DOI: 10.1016/j.drugalcdep.2023.109857.Peer-Reviewed Original ResearchConceptsTrial-level bias scoresOpioid cuesAB taskCognitive bias modification taskAttentional bias taskCognitive bias modificationComputer-based tasksPreliminary efficacyOpioid use disorderCurrent studyBias modificationBias taskBias scoresModification tasksCBM groupCBM tasksChronic painAcceptability measuresControl conditionTaskUse disordersClinical careCuesTime interactionParticipantsOn the Edges: The Ethics of Human Studies with Psychedelic Substances
da Costa S, Sofuoglu M. On the Edges: The Ethics of Human Studies with Psychedelic Substances. 2023, 153-171. DOI: 10.1007/978-3-031-14339-7_9.Peer-Reviewed Original ResearchClinical benefitLife-threatening conditionNovel pharmacological agentsAlcohol use disorderClinical studiesDepressive symptomsHuman studiesPharmacological agentsUse disordersMedical supervisionClassical psychedelicsTherapeutic potentialClinical researchPsychoactive effectsPsychedelic substancesControlled Substances ActHuman researchAccepted medical useConsistent evidenceDisordersPsychedelicsSubstances ActSchedule IMedical useRecreational useOpioid Use Disorder With Chronic Pain Increases Disease Burden and Service Use
MacLean RR, Sofuoglu M, Stefanovics E, Rosenheck R. Opioid Use Disorder With Chronic Pain Increases Disease Burden and Service Use. Psychological Services 2023, 20: 157-165. PMID: 34968125, PMCID: PMC9358616, DOI: 10.1037/ser0000607.Peer-Reviewed Original ResearchConceptsOpioid use disorderChronic painMental health diagnosesService useUse disordersHealth AdministrationConcurrent opioid use disorderHealth diagnosisOngoing opioid epidemicOutpatient service useVeterans Health AdministrationMental health disordersSubstance use diagnosesSingle disorder groupsClinical service useOpioid prescriptionsAdditional comorbiditiesMultinomial regression analysisDisease burdenMedication fillsOpioid epidemicPrescription opiatesMedical conditionsMedical disordersUse diagnoses
2022
Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies
De Aquino J, Bahji A, Gómez O, Sofuoglu M. Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies. Drug And Alcohol Dependence 2022, 241: 109702. PMID: 36434879, PMCID: PMC9772106, DOI: 10.1016/j.drugalcdep.2022.109702.Peer-Reviewed Original ResearchConceptsOpioid withdrawalObservational studySystematic reviewDelta-9-tetrahydrocannabinol administrationPlacebo-controlled clinical trialCannabis useNon-opioid therapeuticsPotential of cannabinoidsDose of opioidsOpioid withdrawal symptomsOpioid use disorderNarrow therapeutic windowExperimental human studiesDose-dependent increaseMain psychoactive constituentPatient characteristicsWithdrawal symptomsClinical trialsPharmacological factorsStudy qualityTherapeutic windowTherapeutic benefitUse disordersHuman studiesAbuse liabilityEffect of progesterone administration in male and female smokers on nicotine withdrawal and neural response to smoking cues: role of progesterone conversion to allopregnanolone
Novick AM, Duffy KA, Johnson RL, Sammel MD, Cao W, Strasser AA, Sofuoglu M, Kuzma A, Loughead J, Morrow AL, Epperson CN. Effect of progesterone administration in male and female smokers on nicotine withdrawal and neural response to smoking cues: role of progesterone conversion to allopregnanolone. Biology Of Sex Differences 2022, 13: 60. PMID: 36274158, PMCID: PMC9590190, DOI: 10.1186/s13293-022-00472-w.Peer-Reviewed Original ResearchConceptsTobacco use disorderProgesterone ratioConversion of progesteroneNicotine withdrawalSmoking cuesTherapeutic effectPlacebo-controlled crossover studySmoking-related outcomesNeural responsesSex-dependent effectsGreater therapeutic benefitDays of abstinenceCrossover studyFemale smokersProgesterone administrationNeurosteroid allopregnanoloneWithdrawal symptomsNicotine effectsWithdrawal severityAllopregnanoloneTherapeutic benefitUse disordersSmoking urgesProgesteroneProgesterone conversionPilot examination of stress, heart rate variability, and alcohol craving and use among female veterans
Holzhauer CG, Epstein EE, Bickar L, Ellis RA, Pole N, Sofuoglu M, Smelson DA, Mattocks K. Pilot examination of stress, heart rate variability, and alcohol craving and use among female veterans. Frontiers In Psychiatry 2022, 13: 886801. PMID: 36159929, PMCID: PMC9500469, DOI: 10.3389/fpsyt.2022.886801.Peer-Reviewed Original ResearchHeart rate variabilityAlcohol use disorderAlcohol cravingAlcohol misuseFemale veteransRate variabilityStudy periodSelf-reported alcohol cravingPilot dataAssociation of stressSelf-report questionnairesUse disordersVeteran populationWomen veteransDaily drinksDaily assessmentAlcohol useDaily cravingPilot studyOverall alcoholCravingSuccessive differencesPotential roleWomenPilot examinationCocaine Use Disorder (CUD): Current Clinical Perspectives
Schwartz EKC, Wolkowicz NR, De Aquino JP, MacLean RR, Sofuoglu M. Cocaine Use Disorder (CUD): Current Clinical Perspectives. Substance Abuse And Rehabilitation 2022, 13: 25-46. PMID: 36093428, PMCID: PMC9451050, DOI: 10.2147/sar.s337338.Peer-Reviewed Original ResearchCocaine use disorderCo-occurring disordersUse disordersCommon co-occurring disordersCurrent clinical perspectivesSubstance use disordersCognitive behavioral therapyMedication treatmentPharmacological treatmentRisk factorsCurrent treatmentDevastating disorderLarger sample sizeTreatment planChronic effectsCocaine useBehavioral treatmentClinical perspectiveBehavioral interventionsDisordersTreatmentFuture studiesMost individualsIndividualsSample sizeProgesterone Increases Nicotine Withdrawal and Anxiety in Male but Not Female Smokers During Brief Abstinence
Novick AM, Duffy KA, Johnson RL, Sammel MD, Cao W, Strasser AA, Sofuoglu M, Kuzma A, Loughead J, Epperson CN. Progesterone Increases Nicotine Withdrawal and Anxiety in Male but Not Female Smokers During Brief Abstinence. Nicotine & Tobacco Research 2022, 24: 1898-1905. PMID: 35713950, PMCID: PMC9653080, DOI: 10.1093/ntr/ntac146.Peer-Reviewed Original ResearchConceptsBrief abstinenceNegative affectNicotine withdrawalNicotine use disorderUse disordersFemale smokersNeural measuresFinal drug administrationSmoking cuesSmoking-related outcomesNeural responsesEffect of progesteroneSmoking urgesMood statesSex-dependent effectsSmoking outcomesNicotine effectsDrug AdministrationAbstinence periodSubjective effectsNicotine dependenceAbstinenceMain effectSignificant sexPlacebo-controlled crossover studyModafinil does not reduce cocaine use in methadone-maintained individuals
DeVito EE, Poling J, Babuscio T, Nich C, Carroll KM, Sofuoglu M. Modafinil does not reduce cocaine use in methadone-maintained individuals. Drug And Alcohol Dependence Reports 2022, 2: 100032. PMID: 36310662, PMCID: PMC9615926, DOI: 10.1016/j.dadr.2022.100032.Peer-Reviewed Original ResearchCocaine use disorderCocaine use outcomesOpioid useCognitive behavioral therapyContingency managementCocaine dependenceCognitive functionMethadone-maintained individualsUse outcomesEfficacy of modafinilSelf-reported abstinenceTreatment of CUDStimulant-like effectsPlatform treatmentPercentage of urinesPercent of daysDual opioidModafinil treatmentUse disordersPotential efficacyCocaine useModafinilPlaceboMinimal reportsBehavioral therapy
2021
Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies
De Aquino JP, Parida S, Avila-Quintero VJ, Flores J, Compton P, Hickey T, Gómez O, Sofuoglu M. Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies. Drug And Alcohol Dependence 2021, 228: 109097. PMID: 34601272, PMCID: PMC8595687, DOI: 10.1016/j.drugalcdep.2021.109097.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderExperimental pain studiesAbuse potentialRespiratory depressionAcute painPain studiesUse disordersSystematic reviewGreater abuse potentialHigh-potency opioidsMethadone-maintained personsSignificant pain reliefRespiratory depressant effectsHigh-potency compoundsOpioid naïveAgonist therapyOpioid dosesPain reliefAnalgesic effectSevere painDepressant effectAdditional dosesStudy qualityHealthy personsThe Impact of Chronic Pain on Opioid Use Disorder Treatment Outcomes
MacLean R, Spinola S, Garcia-Vassallo G, Sofuoglu M. The Impact of Chronic Pain on Opioid Use Disorder Treatment Outcomes. Current Addiction Reports 2021, 8: 100-108. DOI: 10.1007/s40429-020-00352-6.Peer-Reviewed Original ResearchOpioid agonist treatmentChronic painOpioid use disorderOpioid Use Disorder Treatment OutcomesNonpharmacologic pain treatmentsIllicit opioid useDisorder treatment outcomesReviewChronic painOpioid usePain intensityPain treatmentAgonist treatmentOAT clinicsTreatment outcomesClinical carePainUse disordersDrug useRecent FindingsWeHigher likelihoodClinicOutcomesTreatmentMost studiesIntake
2020
Chapter 23 Pharmacological cognitive enhancers
Peltier M, Sofuoglu M. Chapter 23 Pharmacological cognitive enhancers. 2020, 303-320. DOI: 10.1016/b978-0-12-815298-0.00023-x.Peer-Reviewed Original ResearchSubstance use disordersSignificant health problemNovel pharmacological targetsSignificant cognitive deficitsChronic usePharmacological treatmentCandidate medicationsTreatment outcomesTreatment strategiesUse disordersHealth problemsPharmacological targetsCognitive deficitsCognitive enhancementSubstance useCognitive enhancersPotential mechanismsCognitive functioningTreatmentPharmacological cognitive enhancementPharmacological cognitive enhancersMedicationsImpairmentCocaine
2019
Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorder
DeVito EE, Carroll KM, Babuscio T, Nich C, Sofuoglu M. Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorder. Journal Of Substance Use And Addiction Treatment 2019, 107: 29-37. PMID: 31757262, PMCID: PMC6918721, DOI: 10.1016/j.jsat.2019.08.009.Peer-Reviewed Original ResearchConceptsCocaine use disorderSignificant treatment group differencesUse disordersEfficacy of galantamineTreatment-seeking cocaine usersCurrent cocaine use disordersGroup differencesCocaine use outcomesSample of individualsTreatment group differencesComorbid opioid use disorderMethadone-maintained individualsMemory capacityAbstinent individualsCocaine useCognitive improvementCognitive outcomesCocaine use reductionCognitive functionUse outcomesCocaine usersGalantamine groupIndividualsDisordersInitial promiseDouble‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use
Carroll KM, DeVito EE, Yip SW, Nich C, Sofuoglu M. Double‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use. American Journal On Addictions 2019, 28: 238-245. PMID: 31165574, PMCID: PMC9078084, DOI: 10.1111/ajad.12904.Peer-Reviewed Original ResearchConceptsMethadone-maintained individualsOpioid useSecondary analysisMultiple drugsConcurrent cocaine dependenceTrial of galantaminePlacebo-controlled trialDouble-blind placeboIllicit opioid useRandomized clinical trialsCocaine use disorderGalantamine's effectFuture trialsClinical trialsUrine specimenUrine specimensUse disordersOpioidsCholinesterase inhibitorsMaintenance settingCocaine useCocaine dependencePlaceboConcurrent useGalantaminePharmacotherapies for PTSD and Substance Use Disorders
Kachadourian L, Jensen K, Sofuoglu M, Petrakis I. Pharmacotherapies for PTSD and Substance Use Disorders. 2019, 239-259. DOI: 10.4324/9781315442648-13.ChaptersOpioid use disorderAlcohol use disorderPosttraumatic stress disorderUse disordersPTSD/SUDPharmacological treatmentComorbid posttraumatic stress disorderUse of pharmacotherapySubstance use disordersEffectiveness of foodIntramuscular naltrexoneLabel medicationsEpidemiological studiesMedication developmentDrug AdministrationPharmacotherapyStress disorderAvailable evidenceDisordersNew targetsNaltrexoneTreatmentBiological mechanismsSpecific substancesSUD
2018
Minocycline does not affect experimental pain or addiction-related outcomes in opioid maintained patients
Arout CA, Waters AJ, MacLean RR, Compton P, Sofuoglu M. Minocycline does not affect experimental pain or addiction-related outcomes in opioid maintained patients. Psychopharmacology 2018, 236: 2857-2866. PMID: 30564869, PMCID: PMC6581631, DOI: 10.1007/s00213-018-5146-7.Peer-Reviewed Original ResearchConceptsOpioid-induced hyperalgesiaCold pressor testOpioid use disorderSerum cytokinesPain thresholdUse disordersAddiction-related outcomesProinflammatory serum cytokinesActivation of microgliaSeverity of painEcological momentary assessmentEnd of treatmentHuman laboratory studiesTest sessionsOpioid cravingMinocycline treatmentOpioid toleranceAgonist treatmentPain sensitivityVisit 1Minocycline effectsPressor testExperimental painPreclinical studiesGo/No-Go taskPharmacological and Behavioral Treatment of Opioid Use Disorder
Sofuoglu M, DeVito E, Carroll K. Pharmacological and Behavioral Treatment of Opioid Use Disorder. Psychiatric Research And Clinical Practice 2018, 1: 4-15. PMCID: PMC9175946, DOI: 10.1176/appi.prcp.20180006.Peer-Reviewed Original ResearchOpioid use disorderMedication-assisted treatmentSubstance use conditionsBehavioral treatmentTreatment retentionUse disordersBehavioral interventionsOpioid withdrawal symptomsFirst-line treatmentMechanism of actionOUD treatmentComorbid conditionsMedication complianceWithdrawal symptomsClinical overviewClinical guidelinesOpioid receptorsAdrenergic agonistsNonsystematic reviewDrug AdministrationKey pharmacologicalBehavioral therapyTreatment effectivenessComplex needsTreatment